Pharmacogenetics of ugt genes in North African populations

Cytochrome P450 (CYP450), sulfotransferase (SULT), and glucuronidase (UGT) enzymes play roles in the phase I and phase II metabolism of most clinically prescribed drugs. As polymorphisms in these genes may alter enzyme activities, most prescribed drugs will differ in their efficacy and side effects....

Full description

Saved in:
Bibliographic Details
Published in:The pharmacogenomics journal 2018-09, Vol.18 (5), p.609-612
Main Authors: Gaibar, M., Novillo, A., Romero-Lorca, A., Esteban, M. E., Fernández-Santander, A.
Format: Article
Language:English
Subjects:
45/77
631/208/721
692/499
African Continental Ancestry Group - genetics
Africans
Alleles
Biomedical and Life Sciences
Biomedicine
Cancer
Cytochrome P-450
Drug metabolism
Drugs
Enzims
Enzymes
Farmacogenètica
Gene Expression
Genes
Genetic aspects
Genetic polymorphisms
Genetic variation
Glucuronidase - genetics
Health aspects
Human Genetics
Humans
Hydrolases
Industrialized nations
Metabolism
Metabolites
Multiculturalism & pluralism
Mutation
News
North Africa
Oncology
Pharmacogenetics
Pharmacogenetics - methods
Pharmacogenomics
Pharmacotherapy
Polymerase chain reaction
Polymorphism
Polymorphism, Single Nucleotide - genetics
Population
Prescriptions (Drugs)
Psychopharmacology
Universities and colleges
Àfrica del Nord
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cytochrome P450 (CYP450), sulfotransferase (SULT), and glucuronidase (UGT) enzymes play roles in the phase I and phase II metabolism of most clinically prescribed drugs. As polymorphisms in these genes may alter enzyme activities, most prescribed drugs will differ in their efficacy and side effects. In prior work, we showed that besides polymorphisms in CYP450, those in SULT and UGT also give rise to different serum levels of some drug metabolites than detected in wild-type carriers of the genes [1]. [...]
ISSN:1470-269X
1473-1150
DOI:10.1038/s41397-018-0034-4